Compare Globus Medical Inc. Class A Common Stock (GMED) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Prospect Capital Corporation — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.99 (market cap $10.25B), while Prospect Capital Corporation trades at $1.61 (market cap $848.77M). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 12.1× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 26.42% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Prospect Capital Corporation for 78 Days on average.
| GMED | PSEC | |
|---|---|---|
Market Cap | $10.25B | $848.77M |
Volume | 1,059,528 | 7,084,485 |
Sector | Health | Financials |
52-Week High | $96.82 | $3.05 |
52-Week Low | $58.33 | $1.60 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $9.76B | $2.67B |
Dividend Yield | — | 26.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
PSEC trades at $1.67, down 3.47% today, with bearish technical signals dominating. The stock shows mixed fundamentals with a low P/B ratio of 0.3x but negative revenue and net income in 2025. Recent earnings have consistently beaten expectations, though the company faces significant financial volatility with revenue swinging from $635M in 2022 to -$407M in 2025. Dividend distributions continue at $0.04 monthly, providing income appeal despite operational challenges.
The outlook remains cautious with analyst consensus leaning Hold (55%) amid financial instability. Key risks include persistent revenue volatility and negative cash flow. Upside potential exists from consistent earnings beats and deep valuation discounts, but investors should weigh income benefits against fundamental deterioration and bearish technical momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
